All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2020; the latest 2025-01-24.
From the record
Lyell Immunopharma, Inc.'s filings since 2020 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2025-01-24) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-38.4% a year over 7 filed years; profitable in 0 of 6.
From the record
Lyell Immunopharma, Inc.'s 7 filed years say what it did: revenue went from $657 thousand in fiscal 2019 to $36 thousand in fiscal 2025, down 38.4% a year; it rose in 3 of 6 years; the deepest fall was 100% from fiscal 2022 to fiscal 2025; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Lyell Immunopharma, Inc.'s shareholder treatment is put at 6.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 38% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -111%: lost 111¢ per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Lyell Immunopharma, Inc. lost about 111 cents for every dollar of shareholders' money. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 30.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 1% of 315 in its family; net margin -762355.6%.
From the record
Lyell Immunopharma, Inc.'s standing among 315 graded names in its industry family: revenue of $36 thousand in fiscal 2025 ranks in the bottom 3% by size; a net margin of -762355.6% ranks in the bottom 1%; revenue growth of -92.5% a year over the last 3 filed years ranks in the bottom 1% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 44% of 315 in its family for leadership; chief executive since 2022.
From the record
Lyell Immunopharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Seely, Lynn (President and CEO, as filed), filing under that title since 2022-12-19, 3.9 years (bottom 41% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 5.4 years (bottom 43%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 48%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 45% of 273 in its family for room to expand.
From the record
Lyell Immunopharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $62 million against no long-term debt tagged leaves 18.2% of its assets as net cash, bottom 36% of its family; cash from operations less capital spending is -418900% of revenue (bottom 1%); research spending of 440763.9% of revenue (top 1%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 22% of 306 in its family for growth drivers.
From the record
Lyell Immunopharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -92.5% a year over the last three filed years against -38.4% over all 7, slowing (bottom 12% of its family); the newest year grew -41% (bottom 20%); research spending grew -0.1% a year (bottom 48%); capital spending grew -68.2% a year (bottom 8%) (its annual reports). Lyell Immunopharma, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 45% of 233 in its family for expectations against reality.
From the record
Lyell Immunopharma, Inc.'s newest year against its own record: revenue of $36 thousand in fiscal 2025 came in 2093.5% above the $2 thousand its prior three years' pace pointed to (top 4% of its family); net income of $274 million against a prior three-year average of $254 million (bottom 37%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 1%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made